•  
  •  
  •  
  •  

2026-08-12 19:41:30

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  INE101D01020

Stock Report

  • Granules India Reports Strong Q1 FY27 Performance: Net Profit Jumps 59.8% YoY to ₹179.96 Crore
  • Granules India Limited Secures Sole First-to-File ANDA Status for Sodium Oxybate Extended-Release for Oral Suspension
  • Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility
  • Granules India Limited completes cGMP Audit at its Chantilly Site
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Granules India's Packaging Facility in US gets FDA EIR with No Action Indicated Status
  • Granules Pharmaceuticals Inc. receives FDA tentative approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Granules India Ltd receives official 2025 CDP rating
  • Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations
  • Granules India Strengthens R&D Leadership with Two New Centres of Excellence at IIT Hyderabad's Technology Research Park
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • Granules India earns Gold Rating in First-Ever Corporate-Level EcoVadis Assessment Ranks in the Top 5% Globally Across All Industries
  • Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
  • Granules India enters the high growing peptide segment and CDMO business by acquiring Senn Chemicals AG
  • Granules India Limited announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.
  • Granules' Net Zero Commitment Validated and Approved by Science Based Targets Initiative
  • Granules India Ltd announces ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
  • Granules India Unveils 'Breast Health Express' Mobile Unit
  • Granules India's Gagillapur Facility Completes US FDA Inspection with Six Observations
  • Granules India Limited receives ANDA approval for Glycopyrrolate Oral Solution
  • Granules India Limited announced ANDA Approval for Colchicine Capsules
  • US FDA audit of Granules India's Unit V facility results in Zero 483s

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025